Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events

• Main Authors: Pavel Burda (Author), Alzbeta Hlavackova (Author), Vendula Polivkova (Author), Nikola Curik (Author), Adam Laznicka (Author), Jitka Krizkova (Author), Jiri Suttnar (Author), Pavel Klener (Author), Katerina Machova Polakova (Author)
• Format: Book
• Published: Elsevier, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. A substantial part of patients treated with imatinib report skeletomuscular adverse events af...